SVRA's Quarterly Loss Matters Less Than What the FDA Decides Twelve Days Later

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Savara typically reports earnings after the market close, meaning Day 0 reflects anticipation and any after-hours reaction, while Day +1 captures the first full trading session following the release.

Savara's post-earnings price action has been volatile but directionally mixed, with the stock showing a tendency to recover on Day +1 even after initial Day 0 declines. Over the past eight quarters, the average absolute Day 0 move is 3.11%, with an average range of 8.81%, while Day +1 sees a larger average absolute move of 5.23% and a range of 9.49%. The most dramatic reaction came in November 2024, when the stock fell 5.90% on Day 0 and then plunged an additional 15.14% on Day +1, marking the worst two-day performance in the dataset. More recently, the August 2026 report saw a modest 2.79% decline on Day 0 followed by a 2.33% gain on Day +1, reflecting the stock's pattern of intraday volatility followed by next-day reversals. The data suggest investors should expect a move in the high single digits on average, with the potential for double-digit swings in either direction depending on the company's cash burn guidance and any updates on the upcoming PDUFA decision.

Part 2.2: Options Market Expected Move

The options market is pricing a 28.97% expected move by the November 20 monthly expiration, implying a range between $3.50 and $6.36. This is dramatically larger than the stock's average historical earnings move of 3.11% on Day 0 and 5.23% on Day +1, reflecting the fact that this earnings report arrives just nine days before the November 22 PDUFA decision—the most significant binary catalyst in the company's history. The elevated implied volatility of 601.70% and the wide expected move suggest the options market is pricing not just the earnings release itself, but the proximity to the FDA decision and the potential for material updates on cash position, commercial readiness, or regulatory timing.

Part 3: What Analysts Are Saying

Current Analyst Consensus

Savara holds a Strong Buy consensus among Wall Street analysts, with 9 Strong Buy ratings, 0 Moderate Buy ratings, 1 Hold rating, and 0 Sell ratings out of 10 total recommendations. The average rating of 4.80 out of 5.00 reflects overwhelming bullish sentiment. The mean price target stands at $11.05, with a high estimate of $16.00 and a low of $9.00. At the current price of $4.92, the consensus target implies 125% upside, underscoring analysts' confidence that FDA approval of MOLBREEVI on November 22 will unlock substantial value.

Ratings Breakdown and Sentiment Trend

The distribution is heavily skewed toward buy recommendations, with 90% of analysts rating the stock a Strong Buy and only one analyst maintaining a Hold rating. Notably, the sentiment trend is classified as unchanged over the past month, with the same 9 Strong Buy and 1 Hold configuration persisting from one month ago. This stability suggests analysts are maintaining their bullish stance heading into the PDUFA decision rather than adjusting ratings in response to recent volatility or the proximity of the catalyst.

Price Target Implications

The consensus price target of $11.05 represents a significant premium to the current trading level, reflecting the market's view that a successful FDA approval would more than double the stock price. The wide range between the low target of $9.00 and the high of $16.00 illustrates the binary nature of the upcoming decision: approval likely drives the stock toward the upper end of the range, while a rejection or Complete Response Letter would send shares materially lower. JPMorgan's October initiation at $12.00 and Royal Bank of Canada's $10.00 target anchor the bullish case, while the single Hold rating and two recent downgrades to Sell by Wall Street Zen and Weiss Ratings highlight execution risk and the company's history of regulatory setbacks.

Part 4: Technical Picture

Barchart Technical Opinion and Recent Trend

The Barchart Technical Opinion currently registers an 88% Sell signal, unchanged from last week's 88% Sell and slightly improved from last month's 100% Sell. This bearish technical backdrop contrasts sharply with the bullish analyst consensus, reflecting the stock's recent pullback from higher levels earlier in the year. The stock has drifted lower over the past month, declining roughly 7.5% from around $5.32 to the current $4.92, and remains well below its 52-week high of $7.01 reached earlier in 2026.

Timeframe Analysis

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned neutral to slightly negative, consistent with the recent drift lower heading into earnings.
• Medium-term (100% Sell): Strong sell signal reflects sustained weakness in the intermediate timeframe, suggesting the stock has been under distribution pressure as investors await the PDUFA decision.
• Long-term (100% Sell): Strong sell signal points to deterioration in the longer-term trend, with the stock trading below key moving averages and failing to sustain rallies.

Trend Characteristics: The combination of Average strength and Average direction suggests the stock is in a consolidation phase with no clear directional conviction, typical of a name trading in a tight range ahead of a major binary catalyst.

The stock is currently trading at $4.92, positioned above the 5-day ($4.77), 10-day ($4.81), and 20-day ($4.71) moving averages, indicating short-term resilience despite the recent pullback. However, it remains below the 50-day ($4.97), 100-day ($5.33), and 200-day ($5.35) moving averages, confirming the longer-term downtrend and the stock's failure to reclaim key technical levels. The setup heading into earnings is cautionary from a technical perspective: while the stock has found support near current levels, the bearish medium- and long-term signals, combined with the proximity to the November 22 PDUFA decision, suggest the technical picture is secondary to the fundamental catalyst. Investors should expect heightened volatility, with the options market pricing a nearly 29% move by mid-November—far exceeding typical earnings-driven swings and reflecting the binary nature of the FDA decision that will ultimately determine the stock's trajectory.